Reasearch Studies Supporting the Efficacy of VSL#3
Gionchetti P. et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis. Gastroenterology 2000; 119(2):305-309.
Gionchetti P. et al. Prophylaxis of pouchitis onset with probiotic therapy. Gastroeterology 2003; 124(5):1202-1209
Venturi A. et al. Impact on the composition of the fecal flora by a new probiotic preparation. Aliment Pharmacol Ther. 1999; 13(8):1103-1108
Campieri M. et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease. Gastroenterology 2000; 118:A4179
Delia P. et al. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am. J. Gastroenterology 2002; 97(8):13-15.
Kim HJ. et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17:895-904
Bazzocchi G. et al. Changes in symptoms, distension-stimulated colonic motility and in fecal microbiological features after oral bacteriotherapy in patients with diarrhea-predominant IBS (D-IBS) or with functional diarrhea (FD). Am. J. Gastroenterology 2002; 97(9):A847
Mimura T. el al. Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis. Gastroenterology 2002; 122:A81
Brigidi P. et al. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res. Microbiol. 2001; 152:735-41.